AliveDx Suisse S.A. and Medikonia Limited Sign Distribution Agreement in Hong Kong and Macau

AliveDx Suisse S.A. and Medikonia Limited have signed a distribution agreement, which will enable Medikonia to distribute the MosaiQ® solution in Hong Kong and Macau. The distribution agreement takes effect immediately.

AliveDx is committed to broadening its reach and presence across different regions, aiming to generate both clinical and economical value for clinicians, helping them to shorten the time to diagnosis. This new partnership with a significant player in Hong Kong and Macau underscores the company’s dedication to supporting the healthcare sector and enhancing patient care.

The MosaiQ platform simplifies workflows and creates efficiencies thanks to its multiplexing microarray assay technology. This streamlined and efficient approach offers faster and more cost-effective solutions to healthcare providers and patients alike.

“Our partnership with Medikonia represents an important step in our commitment to global growth. We are excited to collaborate with such a strong partner and contribute to the healthcare community in Hong Kong and Macau,” said Manuel O. Méndez, CEO of AliveDx.

Khaled Hamed, Head of Global Emerging Markets at AliveDx added: “I am excited and eager to collaborate with Mr Leon Li and the great team at Medikonia. The Hong Kong and Macau markets are prime examples of developed environments with advanced healthcare facilities. We look forward to contributing to the region’s healthcare system and demonstrating how the MosaiQ solution can enhance diagnostics and improve patient outcomes.”

Established in 2015 and based in Hong Kong, Medikonia is a leading solution provider in biological products and services. The company aims to make research and testing easier by providing innovative and superior value solutions to laboratories in Hong Kong and Macau.

“We are honored to collaborate with AliveDx. One of our group initiatives involves expanding into the in-vitro diagnostics sector. Having the AliveDx solution in our portfolio marks our further expansion into Immunology diagnostic segment. We believe the MosaiQ solution will enable us to provide the Hong Kong and Macau healthcare sector with the latest, best-in-class technologies that will have a positive impact on patients,” said Leon Li, Co-Founder and Chairman of Medikonia.

To learn more, please visit the Medikonia website.

Trending Topics

Our passion for the work we do is matched only by our commitment to consistently provide the best customer experience possible.